Table 3.
The secondary endpoints recorded for Groups A and B before and after administration of dapagliflozin with basal insulin (mean and SD)
| Pre-intervention | Post-intervention | Change by intervention | p value† | ||
|---|---|---|---|---|---|
| Frequency of ketosis, times/day |
A | 0.013 ± 0.019 | 0.086 ± 0.161 | 0.073 ± 0.148 | 0.013 |
| B | 0.013 ± 0.034 | 0.059 ± 0.097 | 0.046 ± 0.085 | 0.011 | |
| p value‡ | 0.91 | 0.46 | 0.4 | ||
| MAGE, mg/dl | A | 121.7 ± 27.7 | 105.0 ± 22.3 | −15.3 ± 18.3 | <0.001 |
| B | 123.4 ± 23.9 | 108.0 ± 23.4 | −13.7 ± 19.8 | 0.003 | |
| p value‡ | 0.81 | 0.65 | 0.77 | ||
| Time-in-range, % | A | 63.6 ± 12.2 | 69.7 ± 11.7 | 6.2 ± 11.1 | 0.007 |
| B | 59.0 ± 16.5 | 69.1 ± 13.4 | 9.4 ± 9.1 | <0.001 | |
| p value‡ | 0.25 | 0.87 | 0.28 | ||
| Time-below-range, % | A | 9.9 ± 9.7 | 12.7 ± 12.6 | 3.1 ± 4.4 | 0.001 |
| B | 7.9 ± 6.8 | 11.4 ± 11.7 | 3.7 ± 6.2 | 0.009 | |
| p value‡ | 0.39 | 0.71 | 0.66 | ||
| Time-above-range, % | A | 26.5 ± 15.4 | 17.6 ± 12.3 | −9.3 ± 11.1 | <0.001 |
| B | 33.1 ± 16.9 | 19.4 ± 13.3 | −13.1 ± 9.4 | <0.001 | |
| p value‡ | 0.14 | 0.61 | 0.2 | ||
| Nocturnal hypoglycemia, % | A | 15.8 ± 18.4 | 20.9 ± 20.5 | 6.4 ± 8.4 | <0.001 |
| B | 11.7 ± 11.6 | 17.5 ± 14.3 | 5.8 ± 10.5 | 0.015 | |
| p value† | 0.33 | 0.51 | 0.81 |
Continuous variables were expressed as mean ± SD. †One-sample t test was applied. ‡Two-sample t test was applied. MAGE mean amplitude of glycemic excursion.